MP 104 - MiGenTra
Alternative Names: MP104MiGenTraLatest Information Update: 30 Mar 2023
At a glance
- Originator MiGenTra
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Mar 2023 Preclinical trials in Cancer in Germany (unspecified route), prior to March 2023 (MiGenTra pipeline, March 2023)
- 11 Jan 2023 MiGenTra plans to launch MP 104 in Egypt in 2025 (MiGenTra pipeline, March 2023)